Artificial Intelligence-Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure.
Journal article
Guimarães P. et al, (2024), Hypertension
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials.
Journal article
Fletcher RA. et al, (2024), Clin J Am Soc Nephrol
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Journal article
Patel SM. et al, (2024), Circulation
Ambulatory blood pressure monitoring and mortality - Authors' reply.
Journal article
de la Sierra A. et al, (2024), Lancet, 403
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Journal article
Wijesurendra RS. et al, (2024), Eur Heart J, 45, 629 - 631
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity
Journal article
Swets MC. et al, (2023), Nature Communications, 14
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Journal article
Mayne K. et al, (2023), Journal of the American Society of Nephrology
UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.
Journal article
Roddick AJ. et al, (2023), BMC Nephrol, 24
Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients.
Journal article
Staplin N. et al, (2023), Lancet, 401, 2041 - 2050
Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
Journal article
Harper C. et al, (2023), Heart
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Journal article
HERRINGTON W. et al, (2023), Kidney International Reports
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2023)
The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts
Journal article
Grams ME. et al, (2023), Journal of the American Society of Nephrology : JASN, 34, 482 - 494
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Journal article
Chapman D. et al, (2023), Kidney Int